Recently, KPMG China released the "2022 First Biotechnology Innovation 50 Enterprises" list. After several rounds of screening and evaluation by the organizer and industry experts for about 10 months, QuaCell finally made it to the list with its strong technical R&D team, strong innovation ability and huge development potential.

The first Biotechnology Innovation 50 Enterprise Selection Event was hosted by KPMG China, aiming to select leading biotechnology innovation companies and create a resource docking platform for biotechnology companies. The selection activity is mainly based on five main core dimensions, including technology and product line leadership, core management team and R&D team background, capital market activity, product pipeline richness, and financial health.

Adhering to the requirements of ISO and GMP regulations, QuaCell focuses on the research and manufacture of cell culture media, providing key raw materials for global biopharmaceutical and gene therapy companies; focusing on customer requirements, providing DNA to GMP production that meets FDA/NMPA requirements The integrated service has won the recognition and trust of more than 200 biopharmaceutical and biotechnology enterprise customers at home and abroad.

This slisting is a high recognition of QuaCell by the selection agency and the market, which is both an honor and a spur. Committed to becoming an "unparalleled partner of biopharmaceutical companies", QuaCell will continue to take customer needs as our responsibility, industry development as the blueprint, and continue to provide high-quality products and services for domestic and global biopharmaceutical clients in the field of cell culture, empowering industrial innovation.